Description
RNK08954 is an experimental oral medication currently being studied in clinical trials for advanced solid tumors, including colorectal cancer. It is specifically being investigated in patients whose tumors have a specific type of KRAS mutation called G12D. The trials are in Phase 1, which means researchers are primarily looking to determine the safest dose and how the drug is processed by the body (pharmacokinetics). The trial design involves starting with a small number of patients at low doses and gradually increasing the dose as the study progresses. Once a safe dose is found, further studies (Phase 1b) will explore its effectiveness in specific cancer types, including colorectal cancer, pancreatic cancer, and others. RNK08954 is not yet approved for any use.
Mechanism of Action
RNK08954 is an oral medication being studied for its potential to treat certain cancers. The specific way it works (its molecular target or mechanism of action) is currently being investigated in clinical trials. It is designed to be taken daily.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.